Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, which has agreed to buy the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback